Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combi G-Vax in Glioblastoma
NCT04523688Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2021
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in glioblastoma (GBM), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Progression-Free Survival at 55 months and Incidence of Treatment-Emergent Adverse Events at 55 months. Started Mar 2021; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04523688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523688.